Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
목요일, 8월 20

Arcutis Biotherapeutics Inc

ARQTNASDAQ
Trade with Public
Trade with Public
$25.35
-1.11-4.2%
가까이에: Aug 20, 5:00 PM EST
$25.64
0.291.14%
시간외: 4:49 PM EST
PRO
변동 이유?:Arcutis Biotherapeutics shares are trading lower. The company announced its...
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Arcutis Biotherapeutics Financials

Arcutis Biotherapeutics (ARQT) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Arcutis Biotherapeutics Q2 EPS $0.11 Beats $0.03 Estimate, Sales $129.861M Beat $118.852M Estimate

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.03 by 266.67 percent. This is a 184.62 percent increase over losses of $(0.13) per
Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Arcutis Biotherapeutics Q1 EPS $(0.09) Misses $(0.06) Estimate, Sales $105.398M Beat $101.261M Estimate

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.06) by 50 percent. This is a 55 percent increase over losses of $(0.20) per share
Benzinga Newsdesk

PRO
Arcutis Biotherapeutics Q4 EPS $0.13 Beats $0.10 Estimate, Sales $129.503M Beat $113.055M Estimate

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.10 by 32.65 percent. This is a 244.44 percent increase over losses of $(0.09) per share
Benzinga Newsdesk

Earnings Scheduled For February 25, 2026

Benzinga Insights

Preview: Arcutis Biotherapeutics's Earnings

Benzinga Insights

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved